| Literature DB >> 33924517 |
Ilias Nikolits1, Sabrina Nebel1, Dominik Egger1, Sebastian Kreß1, Cornelia Kasper1.
Abstract
Mesenchymal stem cells (MSCs) are of great interest for their use in cell-based therapies due to their multipotent differentiation and immunomodulatory capacities. In consequence of limited numbers following their isolation from the donor tissue, MSCs require extensive expansion performed in traditional 2D cell culture setups to reach adequate amounts for therapeutic use. However, prolonged culture of MSCs in vitro has been shown to decrease their differentiation potential and alter their immunomodulatory properties. For that reason, preservation of these physiological characteristics of MSCs throughout their in vitro culture is essential for improving the efficiency of therapeutic and in vitro modeling applications. With this objective in mind, many studies already investigated certain parameters for enhancing current standard MSC culture protocols with regard to the effects of specific culture media components or culture conditions. Although there is a lot of diversity in the final therapeutic uses of the cells, the primary stage of standard isolation and expansion is imperative. Therefore, we want to review on approaches for optimizing standard MSC culture protocols during this essential primary step of in vitro expansion. The reviewed studies investigate and suggest improvements focused on culture media components (amino acids, ascorbic acid, glucose level, growth factors, lipids, platelet lysate, trace elements, serum, and xenogeneic components) as well as culture conditions and processes (hypoxia, cell seeding, and dissociation during passaging), in order to preserve the MSC phenotype and functionality during the primary phase of in vitro culture.Entities:
Keywords: mesenchymal stem cells; optimization cultivation; physiologic cultivation
Year: 2021 PMID: 33924517 PMCID: PMC8069108 DOI: 10.3390/cells10040886
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Different types of basal media.
| Media Name | Description |
|---|---|
| DMEM | Dulbecco’s modified Eagle’s medium (MEM) |
| DMEM/LG/L-G | Dulbecco’s MEM (DMEM) with 1000 mg/mL glucose and L-glutamine |
| DMEM/HG/L-G | DMEM with 4500 mg/mL glucose and L-glutamine |
| DMEM/HG/GL | DMEM with 4500 mg/mL glucose and Glutamax |
| IMDM | Iscove’s modified Dulbecco’s medium with L-glutamine |
| aMEM | MEM alpha |
| aMEM/L-G | MEM alpha with L-glutamine |
| aMEM/GL | MEM alpha with Glutamax |
Human platelet lysate (hPL) as alternative to bovine serum; selected studies from 2005 to 2020 including commercially available products. Information is provided on starting material, preparation technique and culture conditions.
| Starting Material | Solution | Pooled (PC) | Platelet Counts (×109/mL) | Platelet Lysis | Expanded Cells | Supplementation | Outperformed FBS? | Ref. | |
|---|---|---|---|---|---|---|---|---|---|
| (Freeze/Thaw) | (Others) | ||||||||
| Aph-PC | Plasma | 10 | 1 | −80 °C | - | BM-MSC | 5% | yes | [ |
| BC-PC | Plasma | 10–13 | 0.95 | −30 °C | - | UCB-MSC | 10% | yes | [ |
| Exp Aph-PC | Plasma | yes | - | −80 °C | - | BM-MSC | 10% | yes | [ |
| Exp Aph-PC | Plasma | - | - | −80 °C | - | BM-MSC | 5% | no | [ |
| Aph-PC | Plasma | - | - | −80 °C | - | BM-MSC | 8% | no | [ |
| Aph-PC | Plasma | - | 1.0–1.3 | - | S/D | AD-MSC | 10% | no | [ |
| Aph-PC | Plasma | 10 | - | −80 °C | - | BM-MSC, UCB-MSC | 5–10% | yes | [ |
| BC-PC, leuko depleted | Plasma | - | - | −80 °C | - | AD-SC | 5% | yes | [ |
| Aph-PC | Plasma | 4–6 don | - | −80 °C | Sonication | BM-MSC | 10% | yes | [ |
| BC-PC | Plasma | 2 | - | −30 °C | - | BM-MSC, AD-MSC | 2.5–10% | yes | [ |
| BC-PC | Plasma | 2 | - | −30 °C | Thrombin | BM-MSC, AD-MSC | 2.5–10% | yes | [ |
| BC-PC | Saline | 6 | 3.34 | −80 °C | - | AD-MSC | 5% | yes | [ |
| BC-PC | Plasma | 6 | 3.58 | −80 °C | - | AD-MSC | 5% | yes | [ |
| Exp Aph-PC | Plasma | 5 don | 1 | −80 °C | CaCl2 | BM-MSC | 10% | yes | [ |
| Exp BC-PC | Plasma | yes | - | −80 °C | - | BM-MSC | 10% | yes | [ |
| BC-PC, path. Inactivated | Add Sol | 12 don | 1 | −80 °C | - | BM-MSC | 10% | yes | [ |
| BC-PRP | Plasma | 10–20 | 10 | −196 °C | Lyophilization, Irradiation | BM-MSC | 5% | yes | [ |
| PL-Serum | - | 49–109 | - | - | CaCl2 20% | commercial BM-MSC | 10% | yes | [ |
| BC-PC | Plasma | 2 | 2.03 | −25 °C | - | AD-MSC | 1–10% | yes | [ |
| BC-PC | TSOL | 2 | 0.91 | −25 °C | - | AD-MSC | 1–10% | yes | [ |
| Exp BC-PC | Plasma | 2 | 0.41 | −25 °C | - | AD-MSC | 1–10% | yes | [ |
| Exp BC-PC | TSOL | 2 | 0.19 | −25 °C | - | AD-MSC | 1–10% | yes | [ |
| Exp Aph-PC | - | 3–4 don | - | −80 °C | - | AD-MSC | 0.1–1% | yes | [ |
|
|
|
|
|
|
|
|
|
| |
|
|
| ||||||||
| PLTMAX | Sigma Aldrich | yes | - | - | - | AD-MSC | 5% | yes | [ |
| MesenCult hPL media | Stemcell Technologies | yes | - | - | - | AD-MSC | 10% | yes | [ |
| PLUS™ hPL | Compass Biomedical | yes | - | - | - | BM-MSC | 5% | yes | [ |
| PLTmax | MERCK | yes | - | - | - | AD-MSC | 1–10% | yes | [ |
| phPL | PL BioScience | yes | - | - | BM-MSC | 10% | yes | [ | |
(Abbreviations: AD—adipose tissue derived, add sol—additive solution, Aph—apheresis, BC—buffy coat, BM—bone marrow derived, don—donor, Exp—expired, FBS—fetal bovine serum, MSC -mesenchymal stem cell, PC—platelet concentrate, PL—platelet lysate, PRP—platelet rich plasma, S/D—solvent/detergent, UC—umbilical cord derived UCB—umbilical cord blood derived).
Commercially available, chemically defined/serum-free/xeno-free media tested for expansion of hMSCs; including selected studies from 2010–2021. Information is given on brand name, supplier, any added supplements, the cell source, cultivation parameters, and stem cell characteristics.
| Basal Medium | Supplier | Add. Supplements | Cells Expanded | Cultivation Time | Outperformed CTL Medium? | Diff Capacity | Cell Surface Markers | Ref. |
|---|---|---|---|---|---|---|---|---|
| MSCGM-CD | Lonza | - | UC-MSC | 5–7 passages | n.t. | unaltered | unaltered | [ |
| MesenCult | Stemcell Technologies | - | hESC-derived MSCs | - | yes | n.t. | unaltered | [ |
| Mesencult-XF™ | Stemcell Technologies | - | AD-MSC, BM-MSC | - | yes | improved (AD-MSC), decreased (BM-MSC) | altered (BM-MSC) | [ |
| StemPro MSC SFM XenoFree™ | Life Technologies | - | BM-MSC | up to p4 | no | n.t. | n.t. | [ |
| Mesencult-XF™ | Stemcell Technologies | - | BM-MSC | up to p4 | no | unaltered | unaltered | [ |
| BD Mosaic™ Mesenchymal Stem Cell Serum-Free media | BD Biosciences | - | BM-MSC | up to p4 | no | unaltered | unaltered | [ |
| StemPro® MSC SFM XenoFree, Invitrogen | Life Technologies | - | AD-MSC, BM-MSC | - | yes | altered | unaltered | [ |
| StemPro MSC SFM XenoFree™ | Life Technologies | PDGF-BB, bFGF, TGF-β1 | ASC line, BM-MSC | up to p9 | yes | unaltered | unaltered | [ |
| StemPro® MSC SFM | Life Technologies | PDGF-BB, bFGF, TGF-β1 | BM-MSC | 8 passages | no | unaltered | unaltered | [ |
| StemPro MSC SFM Xenofree | Life Technologies | - | BM-MSC, UC-MSC, AD-MSC | 7 days | yes | n.t. | n.t. | [ |
| MSC Nutristem XF | Biological Industries | - | BM-MSC, UC-MSC, AD-MSC | 7 days | yes | n.t. | n.t. | [ |
| MesenCult-XF | Stemcell Technologies | - | BM-MSC, UC-MSC, AD-MSC | 7 days | yes | n.t. | n.t. | [ |
| StemXVivo SFM Human MSC Expansion Medium | R&D Systems | - | BM-MSC, UC-MSC, AD-MSC | 7 days | yes | n.t. | n.t. | [ |
| RoosterNourish-MSC XF | RoosterBio, Inc. | BM-MSC | up to p5 | no | unaltered | unaltered | [ | |
| StemMACS-MSC | Miltenyi Biotec | BM-MSC | up to p5 | no | unaltered | unaltered | [ | |
| MSC NutriStem XF | Biological Industries | BM-MSC | up to p5 | no | unaltered | unaltered | [ | |
| StemXVivo SFM Human MSC Expansion Medium | R&D Systems | BM-MSC | up to p5 | no | unaltered | unaltered | [ |
(Abbreviations: AD—adipose tissue derived, Add.—additional, BM—bone marrow derived, CD—chemically defined, CTL—control, diff—differentiation, hPL - human platelet lysate, MSC—mesenchymal stem cell, n.t.—not tested, p—passage, SFM—serum free medium, UC—umbilical cord derived, XF—xeno-free).
Composition of three disclosed chemically defined cell culture media for MSCs.
|
| [ | [ | [ |
|
| IMDM | IMDM | 17.7 g/L IDMD |
|
| 17.91 ng bovine FGF/mL | 5 mg/mL human serum albumin | 5 mM l-glutamine |
| 2.80 mg/mL human albumin | 100 μg/mL human Ex-Cyte lipoprotein | 3.024 g/L sodium bicarbonate | |
| 27. 65 µM hydrocortisone | 2 μg/mL saturated human transferrin | 10 mg/L rh insulin | |
| 1.18% SITE | 10 μg/mL rh insulin | 10 mg/L rh transferrin | |
| 1.0% 100 × MEM vitamins | 4 g/L rh serum albumin | ||
| 0.89% MEM essential amino acids | 55 μM β-mercaptoethanol | ||
| 0.4% MEM nonessential amino acids | 0.1% chemically defined lipid concentrate | ||
| 1 mM sodium pyruvate | 2% MEM essential amino acids solution | ||
| 1 mM GlutaMAX-I supplement | 1% MEM non-essential amino acid solution | ||
| 10 μg/mL folic acid | 1% Vitamins solution | ||
| 10 μM ascorbic acid 2-phosphate | 0.1% trace elements solution | ||
| 1.0 μg/mL Biotin | 50 μg/L hydrocortisone | ||
| 1.36 μg/mL vitamin B12 mix | 50 mg/L l-ascorbic acid-2-phosphate | ||
| 500fold diluted trace element mix | 5 mg/L rh fibronectin | ||
| 4 × 10−8 M FeSO4 | 5 μg/L progesterone | ||
| 10 μg/mL nucleoside mix | 10 mg/L putrescine | ||
| 2 mg/L serotonin | |||
| 10 ng/mL rh EGF | |||
| 1.0% antibiotic/antimycotic | 10 ng/mL rh basic FGF | ||
| 10–20 ng/mL rh PDGF ββ homodimer | 10 ng/mL rh PDGF | ||
| 10 ng/mL rh IGF |
(Abbreviations: EGF—epidermal growth factor, FGF—fibroblast growth factor, rh—recombinant human, IGF—insulin-like growth factor, IMDM—Iscove’s modified Dulbecco’s medium, MEM—minimum essential media, PDGF—platelet-derived growth factor).
Hypoxic conditions for expansion of hMSC; selected studies from 2007–2020. Information is given on the cell source, exposure to hypoxic conditions and on stem cell characteristics.
| Cells | O2 (%) | Exposure Time | Outperformed 21% O2? | Diff Capacity | Cell Surface Markers | Other Cultivation Parameters Analyzed | Ref. |
|---|---|---|---|---|---|---|---|
| BM-MSC | 2 | 6 weeks | yes | unaltered | n.t. | [ | |
| BM-MSC | 1–3 | 16 h | no | n.t. | n.t. | HGF stimulation | [ |
| BM-MSC | 5 | up to p4 | yes | unaltered | unaltered | hPL | [ |
| BM-MSC | 2 | 14 d | yes | n.t. | unaltered | [ | |
| UC-MSC | 1.5–5 | 3 d | yes | n.t. | n.t. | [ | |
| BM-MSC | 1–5 | 14 d | no | decreased | unaltered | [ | |
| BM-MSC | 1 | 84 days | yes | improved | unaltered | [ | |
| BM-MSC | 5 | up to p3 | yes | improved | unaltered | [ | |
| AD-MSC | 2 | 7 d | yes | improved | unaltered | [ | |
| BM-MSC | 1 | up to 90 d | yes | improved | upregulated | [ | |
| BM-MSC, AD-MSC, AF-MSC, UCB-MSC | 1 | 7 d | depending on cell source (prenatal yes, postnatal no) | n.t. | n.t. | prenatal + postnatal material | [ |
| AD-MSC | 2 | up to 21 d | yes | unaltered | unaltered | [ | |
| UCB-MSC | 5 | 5 d | yes | n.t. | unaltered | [ | |
| AD-MSC | 5 | up to 14 d | yes | n.t. | slightly altered | lean + obese donors | [ |
| BM-MSC | 5 | up to p15 | yes | unaltered | n.t. | donor age | [ |
| BM-MSC | 1–4 | up to p2 | no | unaltered | unaltered | [ | |
| UCB-MSC | 3 | 5 d | yes | unaltered | unaltered | Ca2+ | [ |
| AD-MSC | 5 | up to p28 | yes (until passage 23) | n.t. | n.t. | [ | |
| AD-MSC | 1 | 48 h | yes | decreased (osteogenic) increased (chondrogenic) | unaltered | [ |
(Abbreviations: AD—adipose tissue derived, AF—amniotic fluid BM—bone marrow derived, diff—differentiation, HGF—human growth factors, hPL—human platelet lysate, MSC -mesenchymal stem cell, n.t.—not tested, p—passage, UC—umbilical cord derived, UCB—umbilical cord blood derived).
Figure 1Schematic overview of the aspects improving the standard MSC cultivation setup discussed in this review. The beneficial biological effects are summarized for each topic.